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Abstract
To prevent the accumulation of misfolded and aggregated proteins, the cell has developed a
complex network of cellular quality control (QC) systems to recognize misfolded proteins and
facilitate their refolding or degradation. The cell faces numerous obstacles when performing
quality control on transmembrane proteins. Transmembrane proteins have domains on both sides
of a membrane and QC systems in distinct compartments must coordinate to monitor the folding
status of the protein. Additionally, transmembrane domains can have very complex organization
and QC systems must be able to monitor the assembly of transmembrane domains in the
membrane. In this review, we will discuss the QC systems involved in repair and degradation of
misfolded transmembrane proteins. Also, we will elaborate on the factors that recognize folding
defects of transmembrane domains and what happens when misfolded transmembrane proteins
escape QC and aggregate.
Keywords
transmembrane protein; quality control; autophagy; membrane chaperone; protein folding
1. Introduction
Accumulation of misfolded proteins in a cell can lead to disruption of global protein
homeostasis. To prevent the accumulation of toxic protein species, the cell has developed a
variety of cellular quality control (QC) systems to recognize misfolded proteins and
facilitate their refolding or degradation [1-5]. The cell contains a variety of factors, notably
molecular chaperones, which aid in the folding of proteins and degradation of terminally
misfolded proteins [6]. Failure of protein QC systems to manage protein loads can result in
protein aggregation and formation of toxic protein species, the molecular basis for a number
of diseases.
Transmembrane proteins present interesting problems for QC systems. First, transmembrane
proteins have domains on both sides of a membrane and QC systems in distinct
compartments must coordinate to monitor the folding status of the protein. Second,
transmembrane domains can have very complex organization and QC systems must be able
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to monitor the assembly of transmembrane domains. Several destabilizing mutations in
transmembrane domains of proteins are the basis for several diseases, including cystic
fibrosis, retinitis pigmentosa, hypercholesterolemia, diabetes insipidus, and
hypogonadotropic hypogonadism [7-12] Misfolded transmembrane domains will expose
hydrophilic residues in the hydrophobic environment of the membrane that would normally
be involved in hydrogen bonding to the hydrophobic environment of the membrane (figure
1). Here, we will discuss QC systems used for misfolded polytopic transmembrane proteins,
how the cell recognizes folding defects in transmembrane domains, and what happens when
the transmembrane proteins aggregate.
2. Folding/misfolding of transmembrane proteins
There are two distinct types of transmembrane spanning domains in proteins: β-barrel and α-
helix. α-helix transmembrane spans are common and are inserted into the ER membrane co-
translationally via the Sec61 translocon complex[13]. The translocon, which binds to
ribosomes [14], consists of a complex composed of the Sec61α, β, and γ subunits and
translocating chain-associating membrane protein (TRAM) [15, 16]. Sec61 forms a
hydrophobic tunnel in the membrane that creates a chemical environment in which
translating transmembrane polypeptides can insert into the membrane and achieve proper
structure [17-19]. The Sec61 tunnel can accommodate two helices at one time and facilitate
interhelical bonds between them [20]. However, many proteins have a complex network of
more than two transmembrane spans and the translocon must have a mechanism to prevent
the co-translational aggregation of such proteins (discussed in section 2.2.1). In contrast, the
less common β-barrel transmembrane domains, which are found exclusively on the outer-
membrane of bacteria, chloroplast, and mitochondria, consist of a large coiled β-sheet that
form a pore in the membrane [21]. Folding of the highly ordered β-barrel domain occurs in
the inner membrane space in a process mediated by soluble chaperones such as Skp [22].
Once the proper folding is achieved, β-barrels are post-translationally inserted into the
membrane via an energetically spontaneous process [23].
2.1. QC of polytopic membrane proteins in the ER
Transmembrane proteins can have a wide range of topologies, ranging from proteins
consisting of a single transmembrane α-helix to proteins with more than 20 transmembrane
helices and large soluble domains on both sides of the membrane [13]. To deal with this
variety, multiple ER-membrane associated E3 ubiquitin ligases have been identified that
target different types of terminally misfolded membrane proteins for degradation [24]
(figure 2). The ubiquitin ligase HRD1 forms a functional QC complex with many proteins
including SEL1L, OS-9, the Derlin proteins, and E2 ubiquitin-conjugating enzymes [25-27].
The HRD1 complex has been implicated in the recognition of misfolding in the
transmembrane spans and the ER luminal domains of polytopic membrane proteins. SEL1L
and OS-9 are believed to serve as recognition factors for misfolded ER luminal domains
[24]. Another ubiquitin ligase, GP78, is homologous to HRD1 and is involved in similar QC
processes [28]. The RMA1 E3 ubiquitin ligase functions in a complex with Derlin-1, the E2
ubiquitin-conjugating enzyme UBE2J1, and DNAJB12 [29, 30]. DNAJB12 is a
transmembrane HSP40 chaperone with a cytosolic J-domain that co-operates with cytosolic
Hsp70 to recognize misfolding in cytosolic domains of polytopic membrane proteins,
allowing for RMA1 mediated ubiquitination. Little is known about an additional mammalian
QC ubiquitin ligase, TEB4, but the yeast homolog, Doa10, is involved in QC of polytopic
membrane proteins with cytosolic domains [31]. Recently it was shown that a diverse group
of 24 transmembrane ubiquitin ligases localize to the ER membrane, suggesting that there
may be many uncharacterized transmembrane ubiquitin ligases involved in the QC of
membrane proteins in the ER [32]. Additionally, a host of cytosolic QC factors and ubiquitin
ligase aid in the QC of polytopic membrane proteins with cytosolic domains [2, 33].
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2.1.1 Cystic fibrosis transmembrane conductance regulator (CFTR) as a
model transmembrane QC substrate—The ion-channel cystic fibrosis transmembrane
conductance regulator (CFTR) is a prominent model substrate used in the investigation of
QC of membrane proteins. CFTR is a polytopic membrane protein containing twelve
transmembrane spans, a cytoplasmic regulatory-domain, and two large cytoplasmic
nucleotide-binding domains (NBD1/2) [34]. Mutations in CFTR are the molecular basis for
cystic fibrosis (CF), a common recessive disorder [35, 36]. While over one-thousand
different CF-causing mutations in CFTR have been discovered, 69% of afflicted people
worldwide carry at least one copy of the ΔF508 mutation and as such ΔF508 CFTR is the by
far the most studied CFTR mutant [37]. Phenylalanine-508 of CFTR is part of NBD1 and
deletion of this residue creates a folding defect in the cytoplasmic domains of CFTR [38].
While, ΔF508 CFTR does appear to retain some function, virtually none of the protein
reaches the cell surface. Instead, a network of quality control factors retains ΔF508 CFTR in
the endoplasmic reticulum where it is targeted for proteasomal degradation.
Due to the cytoplasmic folding defect of ΔF508 CFTR, a series of checkpoints involving
both ER and cytoplasmic factors are used in QC. Cytosolic Hsc70 interacts with HSP40, the
U-box ubiquitin ligase CHIP, and the E2 UbcH5 to form an E3 complex that recognizes and
ubiquitinates misfolded ΔF508 CFTR [33, 39, 40]. Additionally, misfolded ΔF508 CFTR is
independently recognized by the ER membrane associated Hsp40 DNAJB12 [29, 30].
DNAJB12 recruits the RMA1 complex to ubiquitinate misfolded CFTR [41]. CFTR that has
been ubiquitinated by RMA1 and/or CHIP is extracted from the membrane into the
cytoplasm via the p97 AAA+ ATPase and degraded by the proteasome.
While the basis for misfolding and recognition of ΔF508 CFTR is an area of intense
investigation, it is not known how the cell would recognize CFTR mutants that cause
misfolding in the transmembrane spans. Of the 20 most common disease-causing CFTR
mutations, three of them are mutations to transmembrane spans (G85E, R347P, and
R334W). However, very little is known about the quality control of these CFTR mutants.
G85E CFTR is degraded before it can exit the ER and none of the protein reaches the cell
surface [42, 43]. Degradation of G85E is dependent on the membrane protein Derlin-1 and it
is suggested that Derlin-1 is serving as a recognition factor for misfolded G85E CFTR [42].
However, much research into the QC mechanisms of misfolded CFTR and other disease-
related transmembrane proteins remains.
2.2. Transmembrane domain chaperones
The key first step in a QC pathway is the recognition of a misfolded protein. Misfolded
soluble proteins typically display hydrophobic patches on the surface of the protein that
would normally be buried in the core. These hydrophobic patches are recognized by
molecular chaperones, allowing the misfolded protein to enter a QC pathway [44]. However,
less is known about the molecular factors that aid in recognition of misfolded
transmembrane domains and the basis for recognition in the lipid bilayer. The proper folding
of α-helix based transmembrane domains is achieved through a series of inter- and intra-
helical hydrogen bonds and salt bridges [45]. A “misfolded” transmembrane domain will
have misaligned helices and may expose polar residues that would normally be involved in
hydrogen bonding to the hydrophobic environment of the membrane (figure 1). A plausible
model is that exposed polar residues could be recognized by molecular chaperones with
active transmembrane domains that monitor the folding status of client transmembrane
domains. Additionally, transmembrane proteins that are unable to properly oligomerize or
form complexes with binding partner will also expose polar/charged residues in the
membrane that can be recognized as misfolded by transmembrane domain chaperones.
While these models of recognition are plausible, no experimental evidence directly confirms
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them. In extreme cases of misfolding, transmembrane helices may not properly insert into
the membrane. The uninserted transmembrane helix will be generally hydrophobic and
exposed in an aqueous environment providing a basis for recognition by cytosolic
chaperones. As an example, an unstable helix in CFTR is often not properly inserted into the
membrane and contributes to improper biogenesis of CFTR [46].
While no transmembrane domain chaperones have been extensively characterized, several
proteins have been identified that could function as transmembrane domain chaperones in
various QC pathways.
2.2.1. The Translocon and TRAM—The Sec61 translocon contains a hollow
hydrophobic tunnel in the membrane that creates a chemical environment in which
translating membrane polypeptides can insert into the membrane and achieve proper folding
[17-19]. The translocon tunnel can accommodate two helices at one time and facilitate
interhelical bonds between them [20]. However, some proteins have a complex network of
more than twenty transmembrane helices and the translocon channel would be unable to
facilitate the organization of such proteins. It has been suggested that translocating chain-
associating membrane protein (TRAM), an essential component of the translocon complex
[15, 16], could act as a transmembrane domain chaperone [47, 48]. Chemical crosslinking
experiments show that TRAM interacts with translocated helices containing charged
residues in translating polypeptides [49, 50]. TRAM contains four relatively hydrophilic
transmembrane helices that could be sites for recognition of exposed charges in client
transmembrane helices [48]. A general model for TRAM as a chaperone would be that it
binds exposed polar/charged residues in already inserted transmembrane helices of
translating polypeptides, preventing aggregation until all the protein has been completely
synthesized so that proper folding can be achieved.
2.2.2. E. coli YidC—In E.coli, the protein YidC has been highly implicated as a key player
in membrane protein biogenesis and shown to be an interactor of the E.coli translocon
[51-53]. Notably, YidC is required for the proper folding of the lactose permease LacY [52].
As LacY contains a very complex 12-membrane spanning domain, with no significant
cytosolic or periplasmic domains, this suggests that YidC is a chaperone that helps organize
complex transmembrane domains. A distantly related mammalian homolog of YidC
(Oxa1L) localizes to the mitochondria and interacts with mitochondrial ribosomes,
suggesting that Oxa1L could have a similar function to YidC in the mitochondria [54].
However, no proteins with any significant homology to YidC are found outside of the
mitochondria and thus there are no YidC-like proteins that could act as a transmembrane
domain chaperone in the ER, where the bulk of membrane protein synthesis takes place.
2.2.3. Yeast Shr3p—Shr3p is an 4 transmembrane spanning protein in yeast that
recognizes, prevents aggregation of, and facilitates refolding of transmembrane domains of
general amino-acid permease 1 (Gap1) [55, 56]. Gap1 contains 12 transmembrane helices
with no significant extracellular or cytoplasmic domains suggesting that Shr3p acts as a
chaperone to fold and organize transmembrane domains. There are no obvious mammalian
homologs of Shr3p.
2.2.4. HRD1—The ER membrane associated ubiquitin-ligase HRD1 is involved in the
degradation of numerous proteins with transmembrane folding defects [24, 57]. Mutations to
the transmembrane domain of HRD1 prevent proteins with misfolded transmembrane
domains, but not ER luminal domains, from being degraded [58]. Additional in vitro studies
suggest that the transmembrane domain of HRD1 directly recognizes misfolded membrane
proteins. A reasonable model is that the transmembrane domain of HRD1 binds misfolded
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transmembrane domains of client proteins, bringing the client protein into a complex with
the cytosolic RING-finger domain, allowing for ubiquitination and proteasomal degradation.
2.2.5. Derlin-1—DerlineIt has been suggested that the known QC factor Derlin-1 can act
as a transmembrane domain chaperones [30]. Derlin-1 forms complexes with membrane
spanning domain 1 (MSD1) of CFTR, which lacks any cytoplasmic structure, and Derlin-1
promotes ER retention and degradation of CFTR [41, 42]. Degradation of G85E CFTR, a
transmembrane domain mutant, is dependent on Derlin-1 and it is suggested that Derlin-1
can serve as a recognition factor for misfolded G85E CFTR [42]. Derlin-1 interacts with the
ER transmembrane ubiquitin ligases RMA1 and HRD1 [24, 41]. An interesting model is that
Derlin-1 provides an additional level of recognition of substrates for these ubiquitin ligases,
in a manner similar to the transmembrane domain of HRD1. While, Derlin-1 is predicted to
have 4 transmembrane spans, recent evidence suggest that it actually has 6 transmembrane
spans which contain a number of polar and charged residues [59].
2.2.6. BAP29/BAP31—BCR-associated proteins 29/31 (BAP29/BAP31) are ubiquitously
expressed transmembrane proteins that form a high molecular weight complex that likely
functions as transmembrane domain chaperones involved in the QC of transmembrane
proteins in the ER. BAP29/BAP31 is involved in the recognition and ER retention of
membrane-bound immunoglobulins (mIgs) with unstable transmembrane domains[60].
However, BAP31 does not interact with and retain an mIg that contains very hydrophobic
and stable transmembrane domains [60]. BAP29 and BAP31 have multiple exposed polar
and charged residues in their transmembrane spans. It is proposed that these polar/charged
residues can interact with exposed hydrophilic sequences in unstable transmembrane spans
of mIgs, providing a molecular basis for recognition and retention [60]. Similarly, BAP31
has been implicated in the ER retention of several other transmembrane proteins with known
unstable transmembrane domains, including CFTR, cellubrevin, and cytochrome P450 2C2
[61, 62]. The fact that BAP29/BAP31 can regulate the ER retention of proteins with diverse
functions and a wide range of topologies suggest that it may be a general ER transmembrane
domain chaperones, rather than a regulator of a specific biological process. An analogous
high molecular weight complex found in the mitochondria, consisting of prohibitin and
BAP37, is involved in the stabilization of membrane proteins in the mitochondria [63].
3. Aggregation and autophagy of transmembrane proteins
Misfolded proteins that escape recognition by molecular chaperones are prone to
aggregation [64]. Aggregates can be toxic to the cell and need to be degraded [65, 66].
Aggregates cannot be degraded by the proteasome as they are physically too large to enter
the narrow proteasomal barrel [67]. While protein aggregates can be disaggregated by
certain molecular chaperones, this does not appear to be the primary mechanism of
aggregate clearance in mammalian cells [68]. Instead, aggregates are often degraded by
macroautophagy [69]. Macroautophagy (simply referred to as autophagy) is a process in
which parts of the cell, such as aggregated or damaged organelles, are packaged into double-
membrane autophagosome and sent to the lysosome for degradation [70]. Unlike the
proteasome, the lysosome is easily capable of degrading large protein aggregates (figure 3).
Recently, there has been a significant amount of investigation into how the cell recognizes
and targets protein aggregates for autophagic degradation.
When the proteasome is inhibited various soluble and integral membrane proteins, including
CFTR, are sent to the aggresome, an inclusion body formed at the microtubule organizing
center [71]. Some proteins targeted to the aggresome are degraded by autophagy, and it has
been suggested that the aggresome may be a sequestration compartment for proteins prior to
autophagic degradation [72, 73]. Additionally, yeast with impaired proteasomal degradation
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accumulate CFTR in an aggresome-like compartment, and eventually degrade it via
autophagy [74]. However, in mammalian cells, CFTR that accumulates during proteasome
inhibition does not appear to be degraded by autophagy suggesting that the aggresome is a
holding compartment for misfolded/aggregated membrane proteins [75].
Very few examples of membrane proteins being degraded by autophagy are found in the
literature. A mutant form of dysferlin, a single transmembrane spanning protein with a large
(>200 amino acids) cytoplasmic domain, has been shown to be partitioned between the
proteasome and the lysosome [76]. Similarly, mutant mouse olfactory receptors have been
shown to accumulate in the presence of lysosome inhibitors, suggesting that they are
degraded by autophagy [77]. While it is clear that membrane proteins can be selected for
autophagy, the mechanism for how membrane proteins are selected for and degraded by
autophagy is entirely unknown.
It is known that many aggregates and inclusion bodies in the cytosol are ubiquitin positive
and that inactivation of autophagy causes a buildup of ubiquitinated aggregates [64, 69, 78].
Specifically, it has been suggested that certain types of polyubiquitin chains will target
proteins to different fates (figure 3) [79]. Soluble proteins being targeted for autophagy will
have K63-linked polyubiquitin chains, while those being targeted for the proteasome will
have primarily K48-linked polyubiquitin chains. Several ubiquitin binding proteins that have
a high affinity for K63-linked polyubiquitin chains, such as p62, NBR1, and HDAC6, have
been implicated in selection of substrates for autophagy [80-82]. This led to the model that
protein aggregates are conjugated with K63-linked polyubiquitin chains and selected for
autophagy by these ubiquitin binding proteins [78, 79]. This model is controversial as it has
been shown that in autophagy deficient mice, all types of polyubiquitin linkages accumulate
and not just K63-linkages [83]. This seems to suggest that ubiquitination of aggregated
protein is merely an indirect consequence. However, as there is tight crosstalk between
proteasomal and autophagic degradation pathways [84, 85] it is unclear exactly what the
expected results would be in these experiments.
A disease-causing mutant of the soluble protein α1-antitrypsin is known to be degraded by
autophagy in an ubiquitin independent manner. When overexpressed, the Z-variant of α1-
antitrypsin (ATZ) will aggregate in the ER lumen and sections of the ER containing these
aggregates are selectively packaged into autophagosomes [86, 87]. While, the exact
mechanism for autophagic degradation of ATZ is not clear, it is possible that aggregated
transmembrane proteins in the ER could be degraded by the same mechanism as luminal
ATZ aggregates.
4. Concluding remarks
Many major questions remain about how the cell deals with misfolded membrane proteins.
First, what QC factors are responsible for the recognition of misfolded transmembrane
spans? As discussed in section 2.2, several proteins have been implicated as transmembrane
domain chaperones, however the mechanism by which most of these proteins act and the
diversity of their substrates remains poorly understood. Also, how are aggregated membrane
proteins selected for autophagy? Is this via ubiquitin dependant autophagy, or perhaps a
process similar to autophagy of ATZ aggregates in the ER lumen? As only several examples
of transmembrane proteins that are degraded by autophagy have been described, the ability
to answer this question will depend on the identification and characterization of more
transmembrane proteins that are degraded by autophagy. Answers to these questions will
give insight into the fundamental biological mechanisms that are the basis for a diverse set
of diseases.
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We discuss the basis for unfolding of transmembrane proteins.
We discuss the quality control pathways responsible for recognition of misfolded
transmembrane.
We discuss what happens when transmembrane proteins aggregate.
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Figure 1. Quality control of a protein with a misfolded transmembrane domain
A misfolded transmembrane protein may have improperly aligned transmembrane helices.
These helices will display polar residues on the surface of the helix (indicated with stars)
that can be recognized by membrane chaperones. Chaperones will prevent the misfolded
protein from aggregating, potentially allowing for the refolding. Terminally misfolded
proteins will be degraded by the proteasome. Proteins that escape chaperone recognition will
aggregate and be degraded by autophagy.
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Figure 2. ER-membrane localized complexes that target misfolded membrane proteins for
degradation
Misfolded membrane proteins are recognized by various ER factors, such as molecular
chaperones, and directed towards ER membrane associated E3 ubiquitin-ligases. The three
main mammalian ligases identified are HRD1, RMA1 and TEB4. Each ligase is part of a
complex with an E2 ubiquitin-conjugating enzyme and other proteins that are involved in
recognition. HRD1 substrates tend to have folding defects in luminal and transmembrane
domains. RMA1 substrates are polytopic membrane proteins with large cytoplasmic
domains. Substrate proteins are ubiquitinated by the respective ligase, extracted into the
cytoplasm via the p97 AAA+ ATPase, and degraded by the proteasome.
Houck and Cyr Page 14













Figure 3. Model for the partitioning of misfolded membrane proteins between autophagy and
proteasomal degradation
Native proteins are prone to unfolding. Unfolded membrane proteins with cytosolic domains
can be recognized by molecular chaperones (i.e. HSP70), preventing aggregation. The
unfolded protein will be refolded or targeted for proteasomal degradation by ubiquitin
ligases (i.e. CHIP) via K48-linked poly ubiquitin chains. Additionally, Misfolded/unfolded
proteins are prone to aggregation. Aggregated proteins can be resolubilized by disaggregates
or degraded by autophagy. Aggregates may be conjugated with K63-linked polyubiquitin
chains. The ubiquitin binding protein p62 will bind K63-linked polyubiquitin chains and
facilitate the packaging of aggregates into autophagosomes. Autophagosomes will fuse with
the lysosome and aggregates will be degraded. Additionally, it is possible that membrane
protein aggregates could be degraded by microautophagy, an autophagosome independent
form of autophagy.
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